Johnson and Johnson 2015 Annual Report Download - page 73

Download and view the complete annual report

Please find page 73 of the 2015 Johnson and Johnson annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 112

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112

Income Before Tax Identifiable Assets
(Dollars in Millions) 2015(3) 2014(4) 2013(5) 2015 2014
Consumer $1,787 1,941 1,973 20,772 21,813
Pharmaceutical 11,734 11,696 9,178 26,144 25,803
Medical Devices 6,826 7,953 5,261 40,979 41,445
Total 20,347 21,590 16,412 87,895 89,061
Less: Expense not allocated to segments (1) 1,151 1,027 941
General corporate (2) 45,516 41,297
Worldwide total $19,196 20,563 15,471 $133,411 130,358
Additions to Property,
Plant & Equipment
Depreciation and
Amortization
(Dollars in Millions) 2015 2014 2013 2015 2014 2013
Consumer $544 581 533 $559 577 539
Pharmaceutical 1,063 977 856 929 1,053 1,075
Medical Devices 1,631 1,807 1,724 1,945 1,974 2,224
Segments total 3,238 3,365 3,113 3,433 3,604 3,838
General corporate 225 349 482 313 291 266
Worldwide total $3,463 3,714 3,595 $3,746 3,895 4,104
Sales to Customers Long-Lived Assets(6)
(Dollars in Millions) 2015 2014 2013 2015 2014
United States $35,687 34,782 31,910 36,609 36,835
Europe 15,995 18,947 18,599 20,167 21,559
Western Hemisphere excluding U.S. 6,045 7,160 7,421 2,881 3,210
Asia-Pacific, Africa 12,347 13,442 13,382 2,493 2,438
Segments total 70,074 74,331 71,312 62,150 64,042
General corporate 1,148 1,138
Other non long-lived assets 70,113 65,178
Worldwide total $70,074 74,331 71,312 133,411 130,358
See Note 1 for a description of the segments in which the Company operates.
Export sales are not significant. In 2015 and 2014, the Company had one wholesaler distributing products for all three
segments that represented approximately 12.5% and 11.0%, respectively, of the total consolidated revenues. In 2013, the
Company did not have a customer that represented 10.0% of total revenues.
(1) Amounts not allocated to segments include interest (income) expense, noncontrolling interests and general corporate (income)
expense.
(2) General corporate includes cash, cash equivalents and marketable securities.
(3) The Medical Devices segment includes a restructuring charge of $590 million, an intangible asset write-down of $346 million related
to Acclarent, Synthes integration costs of $196 million and $148 million expense for the cost associated with the DePuy ASR TM Hip
program. Includes $224 million of in-process research and development expense, comprised of $214 million and $10 million in the
Pharmaceutical and Medical Devices segments, respectively. Includes net litigation expense of $141 million comprised of $136
million in the Pharmaceutical segment and $5 million in the Medical Devices segment, which included the gain from the litigation
settlement agreement with Guidant for $600 million. The Medical Devices Segment includes a gain of $1.3 billion from the divestiture
of the Cordis business. The Pharmaceutical segment includes a gain of $981 million from the U.S. divestiture of NUCYNTA®and a
positive adjustment of $0.5 billion to previous reserve estimates, including Managed Medicaid rebates. The Consumer segment
includes a gain of $229 million from the divestiture of SPLENDA®brand.
(4) Includes net litigation expense of $1,253 million comprised of $907 million, $259 million and $87 million in the Medical Devices,
Pharmaceutical and Consumer segments, respectively. Includes $178 million of in-process research and development expense,
comprised of $147 million and $31 million in the Pharmaceutical and Medical Devices segments, respectively. The Medical Devices
segment includes a net gain of $1,899 million from the divestiture of the Ortho-Clinical Diagnostics business, Synthes integration
Johnson & Johnson 2015 Annual Report •61